Phase 2 Ovarian Cancer Trial, Completed NCT00008138 Sponsor: SWOG Cancer Research Network Condition: Ovarian Cancer
Back to Ovarian Cancer

Trial results

AI generated results summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

According to the results reported on ClinicalTrials.gov, this trial enrolled 58 participants, all of whom were in a single treatment group that received a sequence of chemotherapy before surgery, followed by debulking (tumour-removing) surgery, and then further chemotherapy delivered directly into the abdomen. The trial was measuring two main things: how long participants lived overall, and how long they lived without their cancer getting worse (called "progression-free survival"). The reported data shows that, looking at overall survival — that is, the time from when a participant joined the trial until death from any cause — the reported figure was 32 months. For progression-free survival — the time until the cancer showed signs of worsening, or until death — the reported figure was 21 months. Of the 58 people who started the initial chemotherapy phase, 38 went on to the surgery phase, and 26 then began the final chemotherapy phase, with 18 completing it. The reasons why participants did not continue at each stage were not broken down in the data provided. These are the results as reported to ClinicalTrials.gov. They are not medical advice — always discuss what they mean for you with your doctor.

These are the results as reported to ClinicalTrials.gov, not medical advice. Verify independently with the trial site and discuss what they mean for you with your doctor.

Phase 2 Ovarian Cancer Trial, Completed

NCT00008138
Completed Phase 2

voxsanity.com.au · Eligibility summary from public government registries · 18 August 2026 · not medical advice

Who may and may not be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who may be able to join

  • You have been diagnosed with stage III or IV ovarian cancer, primary peritoneal cancer, or fallopian tube cancer, confirmed by a tissue or cell sample
  • Your cancer is a specific type called adenocarcinoma, and you have a large pelvic or abdominal tumour and/or fluid build-up around the lungs
  • Your doctors believe it is unlikely that surgery could remove most of the tumour
  • Your blood test shows a CA 125 level of at least 70 units/mL (a tumour marker measured in blood)
  • You are reasonably active and able to care for yourself (confirm with trial site for exact fitness level required)
  • Your blood cell counts are within acceptable ranges — enough white blood cells and platelets
  • Your liver is functioning well enough, based on blood tests
  • Your kidneys are working well enough to filter waste from your blood
  • You are not pregnant or breastfeeding, and if you could become pregnant, you are using effective contraception

Who may not be able to join

Each point below is a reason the trial team may not be able to accept someone. It is not a list of requirements to meet.

  • Your tumour is classified as "borderline" or "low-malignant potential" (a less aggressive tumour type)
  • Your stage IV cancer involves spread to the liver tissue, lungs, or other distant organs (fluid around the lungs only is acceptable)
  • You have heart failure, an irregular heartbeat, or have had a heart attack or chest pain (angina) within the last 6 months
  • You have significant nerve damage causing numbness or similar symptoms (confirm with trial site)
  • You have severe stomach or bowel problems, such as a partial blockage or bleeding
  • You have had another cancer within the last 5 years (with some exceptions for certain early-stage or skin cancers that were fully treated)
  • You have an active infection that is not under control
  • You have previously received chemotherapy, immunotherapy, or radiation to the pelvis for this cancer
  • You have previously had major surgery to remove the tumour (such as removal of both ovaries, the uterus, and the omentum together)
  • You are currently receiving any other cancer treatment

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 2 July 2026

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Completed
Phase
Phase 2
Sponsor
SWOG Cancer Research Network
Registry
ClinicalTrials.gov
Start date
1 March 2001
Est. completion
1 September 2009

Primary endpoints

Overall Survival; Progression-Free Survival

Other options

Expanded access pathways

This trial is not enrolling. Other access pathways exist in general: in Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients. Whether it applies to any treatment studied here is a question for your doctor — nothing on this page says it does.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 2 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov